Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:06:30.255Z.
Calculation as of: 2026-10-06T19:06:30.255Z.
Quote observation: 2026-10-06T19:05:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d443e069440aa0ac5a32f25afa0d38c48efe58a411ec60778b8439bb1c5cf92a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Eledon Pharmaceuticals, Inc.
Market Cap
$189.50M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$192.92M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$184.32M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$179.95M
EBITDA Yield
N/A
TTM Avg
7985.41%
3Y Avg
7985.41%
5Y Avg
7985.41%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | $189.50M | N/A | N/A | N/A | N/A |
| RxSight, Inc. (RXST)vs › | $191.96M | N/A | N/A | N/A | N/A |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $192.92M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $184.32M | N/A | N/A | N/A | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $184.22M | N/A | N/A | N/A | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $182.79M | N/A | N/A | N/A | N/A |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $180.89M | N/A | N/A | N/A | N/A |
| Yarrow Bioscience Inc (YARW)vs › | $179.95M | N/A | 7985.41% | 7985.41% | 7985.41% |
| Surrozen, Inc. (SRZN)vs › | $199.98M | N/A | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $198.65M | N/A | 6.19% | 6.19% | 6.19% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
